secwatch.observer — SEC 8-K summary
======================================

Issuer:     Electromedical Technologies, Inc (EMED)
CIK:        0001715819
Form:       8-K
Filed at:   2023-02-01T23:59:59+00:00
Accession:  0001104659-23-009306
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 3.03, 5.01, 5.02, 5.03
LLM model:  deepseek-v4-flash:cloud@v2

CEO Matthew Wolfson granted voting control via Series B preferred; authorized shares increased to 2B+
--------------------------------------------------------------------------------

- Employment agreement gives Wolfson one Series B preferred share with voting control equal to all common shares plus 100k votes on fully diluted basis.
- Wolfson retains $265k/yr CEO salary plus $100k/yr CFO salary; incentives include up to 25M common shares for annual growth and cash bonuses for quarterly growth.
- Robert L. Hymers III appointed as independent director and compensation committee member for 6-month term; receives $5k monthly in common shares.
- Charter amendment increases authorized capital to 2,000,000,001 shares (199M common, 1M Series A preferred, 1 Series B preferred); filed with Delaware.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1715819/000110465923009306/0001104659-23-009306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1715819/000110465923009306/tm235211d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-009306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer